On Mar. 9, 2021, VBI Vaccines announced the initiation of enrollment of its Phase 1/2 clinical study of VBI-2902, the Companyﾒs monovalent enveloped virus-like particle (eVLP) COVID-19 vaccine candidate.

The adaptive Phase 1/2 clinical study was randomized, observer-blind, placebo-controlled, and will evaluate the safety, tolerability, and immunogenicity of VBI-2902, adjuvanted with aluminum phosphate.